Login
$PTCT
$60.97 -$2.52 (3.97%) Live

$PTCT 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Regulation FD Disclosure; Other Events

WARREN, N.J., Nov. 3, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company’s outstanding shar...

29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue –

21 Sep 2026 8-K: Regulation FD Disclosure; Other Events

WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene th...

28 Aug 2026 8-K: Entry into a Material Definitive Agreement

On August 25, 2026, PTC Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Sangamo Therapeutics, Inc. (“Sangamo”), pursuant to which the Company agreed to acquire from Sangam...

13 Aug 2026 8-K: Regulation FD Disclosure; Other Events

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –

30 Jul 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue –

18 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of June 18, 2026 between PTC Therapeutics, Inc., a Delaware corporation, as issuer (the “Company,” as more fully set forth in ‎Section 1.01) and U.S. Bank Trust Company, National Association, a national banking associa...

16 Jun 2026 8-K: Other Events

Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

09 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

stock options to purchase 3,475 shares granted on January 2, 2026 with an exercise price of $76.74 per share, of which 1,447 have vested.

05 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 10, 2026, there w...

07 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –

28 Apr 2026 8-K: Regulation FD Disclosure

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - ​

25 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

WARREN, N.J., March 25, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive li...

19 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –

12 Feb 2026 8-K: Regulation FD Disclosure

WARREN, N.J., Feb. 12, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dy...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –

29 Dec 2025 8-K: Entry into a Material Definitive Agreement

On December 29, 2025, PTC Therapeutics, Inc. (the “Company”), Royalty Pharma Investments 2019 ICAV (“RPI”), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendme...

04 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30–

19 Aug 2025 8-K: Regulation FD Disclosure

WARREN, N.J., August 19, 2025 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone...

07 Aug 2025 8-K: Entry into a Material Definitive Agreement

On August 5, 2025, PTC Therapeutics, Inc. (the “Company”), certain of the former securityholders of Censa Pharmaceuticals, Inc., a Delaware corporation (“Censa”), and, for the limited purposes set forth in the agreement, Shareholder Repr...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support